Publicis launches Razorfish Health as standalone

Share this article:
Katy Thorbahn
Katy Thorbahn
It's not exactly news that Razorfish has a health practice, but the digital agency, which was acquired by Publicis last year, is making it official with the launch of Razorfish Health, an “independent, dedicated” health and wellness agency.

The shop will be headquartered in Philadelphia and headed by general manager Katy Thorbahn, who previously led the Seattle-based firm's Philly shop. She will report to David Kramer, CEO of sibling shop Digitas Health.

Razorfish chief Bob Lord said in a statement: “For more than 13 years, Katy's team has been building relationships with health clients, and it's now time to take our next step with the launch of this brand.”

“Healthcare is a different industry than any other, and that's why we're making this dedicated effort,” said Thorbahn. “Both the healthcare industry and technology in general are experiencing landmark change, and with that enormous opportunities to create direct connections with patients, caregivers and healthcare professionals.”

The shop also unveiled a redesigned website, at razorfishhealth.com, featuring “The Health Conversation,” a social tool that pulls in content from Twitter and Digg based on health categories every ten minutes, illustrating trending topics.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...